Phosphorylation of cardiac myosin binding protein-C (cMyBP-C) is a determinant of cardiac
myofilament function. Although cMyBP-C phosphorylation by various protein kinases has …

The second-generation myosin activator danicamtiv (DN) has shown improved function
compared with the first-generation myosin activator omecamtiv mecarbil (OM) in nonfailing …

Heart failure is a syndrome that can result from impaired heart muscle contractions like in
dilative cardiomyopathy but also from hypertrophic obstructive cardiomyopathy (HOCOM). A …

Background Omecamtiv mecarbil (OM) and danicamtiv both increase myocardial force
output by selectively activating myosin within the cardiac sarcomere. Enhanced force …

Biophysical models are increasingly used to gain mechanistic insights by fitting and
reproducing experimental and clinical data. The inherent variability in the recorded datasets …

Phosphorylation, as one of the most important post-translational modifications, plays a key
role in various cellular physiological processes and disease occurrences. In recent years …

Cardiac myosin binding protein C (cMyBPC) is an 11-domain sarcomeric protein (C0–C10)
integral to cardiac muscle regulation. In vitro studies have demonstrated potential functional …

This study focuses on mimicking constitutive phosphorylation in the N-terminus of the
myosin regulatory light chain (S15D-RLC) as a rescue strategy for mutation-induced cardiac …

Modulation of sarcomere contractility represents a new therapeutic opportunity for the
treatment of heart failure by directly targeting the thick and thin filament proteins of the …

Omecamtiv mecarbil (OM) is a selective cardiac myosin activator. We studied the effects of
OM on the characteristics of contractility under mechanical loads of right ventricular …